Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome

OncoImmunology

Volumn 5, Issue 9, 2016, Pages

  Wang, Linan ^a   Ma, Ning ^b   Okamoto, Sachiko ^c   Amaishi, Yasunori ^c   Sato, Eiichi ^d   Seo, Naohiro ^a   Mineno, Junichi ^c   Takesako, Kazutoh ^d   Kato, Takuma ^a,e   Shiku, Hiroshi ^a,e  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c TAKARA BIO INC   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e MIE UNIVERSITY   (Japan)

Author keywords

Adoptive T cell therapy; carcinoembryonic antigen; chimeric antigen receptor; cytokine release syndrome; neurotoxicity; preconditioning

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE SYNDROME; CYTOTOXICITY; GENETIC TRANSDUCTION; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION; MALNUTRITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR REGRESSION; WEIGHT REDUCTION;

EID: 84983802559     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1211218     Document Type: Article

References (52)

1. M.Vitale, G.Pelusi, B.Taroni, G.Gobbi, C.Micheloni, R.Rezzani, F.Donato, X.Wang, S.Ferrone. HLA class I antigen down-regulation in primary ovary carcinoma lesions:association with disease stage. Clin Cancer Res 2005; 11:67-72; PMID:15671529
2. M.L.Davila, I.Riviere, X.Wang, S.Bartido, J.Park, K.Curran, S.S.Chung, J.Stefanski, O.Borquez-Ojeda, M.Olszewska et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6:224ra25; PMID:24553386; http://dx.doi.org/10.1126/scitranslmed.3008226
3. J.N.Kochenderfer, M.E.Dudley, S.H.Kassim, R.P.Somerville, R.O.Carpenter, M.Stetler-Stevenson, J.C.Yang, G.Q.Phan, M.S.Hughes, R.M.Sherry et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33:540-9; PMID:25154820; http://dx.doi.org/10.1200/JCO.2014.56.2025
4. S.L.Maude, N.Frey, P.A.Shaw, R.Aplenc, D.M.Barrett, N.J.Bunin, A.Chew, V.E.Gonzalez, Z.Zheng, S.F.Lacey et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Eng J Med 2014; 371:1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
5. M.Kalos, B.L.Levine, D.L.Porter, S.Katz, S.A.Grupp, A.Bagg, C.H.June. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/10.1126/scitranslmed.3002842
6. D.W.Lee, J.N.Kochenderfer, M.Stetler-Stevenson, Y.K.Cui, C.Delbrook, S.A.Feldman, T.J.Fry, R.Orentas, M.Sabatino, N.N.Shah et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:a phase 1 dose-escalation trial. Lancet 2015; 385:517-28; PMID:25319501; http://dx.doi.org/10.1016/S0140-6736(14)61403-3
7. S.A.Grupp, M.Kalos, D.Barrett, R.Aplenc, D.L.Porter, S.R.Rheingold, D.T.Teachey, A.Chew, B.Hauck, J.F.Wright et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Eng J Med 2013; 368:1509-18; PMID:23527958; http://dx.doi.org/10.1056/NEJMoa1215134
8. M.Casucci, R.E.Hawkins, G.Dotti, A.Bondanza. Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunol Immunother 2015; 64:123-30; PMID:25488419; http://dx.doi.org/10.1007/s00262-014-1641-9
9. A.Fichera, F.Michelassi, R.B.Arenas. Selective expression of carcinoembryonic antigen promoter in cancer cell lines:targeting strategy for gene therapy in colorectal cancer. Dis Colon Rectum 1998; 41:747-54; PMID:9645743; http://dx.doi.org/10.1007/BF02236263
10. M.Nap, K.Mollgard, P.Burtin, G.J.Fleuren. Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult. Tumour Biol 1988; 9:145-53; PMID:3399813; http://dx.doi.org/10.1159/000217555
11. Z.Yan, X.Deng, M.Chen, Y.Xu, M.Ahram, B.F.Sloane, E.Friedman. Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells. J Biol Chem 1997; 272:27902-7; PMID:9346938; http://dx.doi.org/10.1074/jbc.272.44.27902
12. N.Beauchemin, A.Arabzadeh. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Met Rev 2013; 32:643-71; PMID:23903773; http://dx.doi.org/10.1007/s10555-013-9444-6
13. K.F.Nolan, C.O.Yun, Y.Akamatsu, J.C.Murphy, S.O.Leung, E.J.Beecham, R.P.Junghans. Bypassing immunization:optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999; 5:3928-41; PMID:10632322
14. P.C.Emtage, A.S.Lo, E.M.Gomes, D.L.Liu, R.M.Gonzalo-Daganzo, R.P.Junghans. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo:a preclinical evaluation. Clin Cancer Res 2008; 14:8112-22; PMID:19088026; http://dx.doi.org/10.1158/1078-0432.CCR-07-4910
15. M.R.Parkhurst, J.C.Yang, R.C.Langan, M.E.Dudley, D.A.Nathan, S.A.Feldman, J.L.Davis, R.A.Morgan, M.J.Merino, R.M.Sherry et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19:620-6; PMID:21157437; http://dx.doi.org/10.1038/mt.2010.272
16. R.Bos, S.van Duikeren, H.Morreau, K.Franken, T.N.Schumacher, J.B.Haanen, S.H.van der Burg, C.J.Melief, R.Offringa. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008; 68:8446-55; PMID:18922918; http://dx.doi.org/10.1158/0008-5472.CAN-08-1864
17. M.M.Opata, R.Stephens. Early decision:effector and effector memory T cell differentiation in chronic infection. Curr Immunol Rev 2013; 9:190-206; PMID:24790593; http://dx.doi.org/10.2174/1573395509666131126231209
18. A.M.Eades-Perner, H.van der Putten, A.Hirth, J.Thompson, M.Neumaier, S.von Kleist, W.Zimmermann. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 1994; 54:4169-76; PMID:8033149
19. J.A.Thompson, A.M.Eades-Perner, M.Ditter, W.J.Muller, W.Zimmermann. Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice:an animal model for CEA-directed tumor immunotherapy. Int J Cancer J Int Du Cancer 1997; 72:197-202; PMID:9212243; http://dx.doi.org/10.1002/(SICI)1097-0215(19970703)72:1%3c197::AID-IJC28%3e3.0.CO;2-F
20. S.L.Maude, D.T.Teachey, D.L.Porter, S.A.Grupp. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 2015; 125:4017-23; PMID:25999455; http://dx.doi.org/10.1182/blood-2014-12-580068
21. J.P.Konsman, P.Parnet, R.Dantzer. Cytokine-induced sickness behaviour:mechanisms and implications. Trends Neurosci 2002; 25:154-9; PMID:11852148; http://dx.doi.org/10.1016/S0166-2236(00)02088-9
22. M.Solmi, N.Veronese, A.Favaro, P.Santonastaso, E.Manzato, G.Sergi, C.U.Correll. Inflammatory cytokines and anorexia nervosa:A meta-analysis of cross-sectional and longitudinal studies. Psychoneuroendocrinol 2015; 51:237-52; PMID:25462897; http://dx.doi.org/10.1016/j.psyneuen.2014.09.031
23. J.Stella, C.Croney, T.Buffington. Effects of stressors on the behavior and physiology of domestic cats. Appl Anim Behav Sci 2013; 143:157-63; PMID:25210211; http://dx.doi.org/10.1016/j.applanim.2012.10.014
24. Y.K.Choi, K.Y.Jung, S.-M.Woo, Y.J.Yun, C.-Y.Jun, J.H.Park, Y.C.Shin, S.G.Cho, S.G.Ko. Effect of Sipjeondaebo-tang on cancer-induced anorexia and cachexia in CT-26 tumor-bearing mice. Mediators Inflamm 2014; 2014:736563; PMID:24963216; http://dx.doi.org/10.1155/2014/736563
25. S.L.Maude, D.Barrett, D.T.Teachey, S.A.Grupp. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014; 20:119-22; PMID:24667956; http://dx.doi.org/10.1097/PPO.0000000000000035
26. M.A.Gerber, S.N.Thung. Carcinoembryonic antigen in normal and diseased liver tissue. Am J Pathol 1978; 92:671-9; PMID:356625
27. J.R.Park, D.L.Digiusto, M.Slovak, C.Wright, A.Naranjo, J.Wagner, H.B.Meechoovet, C.Bautista, W.C.Chang, J.R.Ostberg et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007; 15:825-33; PMID:17299405; http://dx.doi.org/10.1038/sj.mt.6300104
28. C.H.Lamers, S.Sleijfer, S.van Steenbergen, P.van Elzakker, B.van Krimpen, C.Groot, A.Vulto, M.den Bakker, E.Oosterwijk, R.Debets et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells:clinical evaluation and management of on-target toxicity. Mol Ther 2013; 21:904-12; PMID:23423337; http://dx.doi.org/10.1038/mt.2013.17
29. C.H.Lamers, S.Sleijfer, A.G.Vulto, W.H.Kruit, M.Kliffen, R.Debets, J.W.Gratama, G.Stoter, E.Oosterwijk. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX:first clinical experience. J Clin Oncol 2006; 24:e20-2; PMID:16648493; http://dx.doi.org/10.1200/JCO.2006.05.9964
30. S.C.Katz, R.A.Burga, E.McCormack, L.J.Wang, W.Mooring, G.R.Point, P.D.Khare, M.Thorn, Q.Ma, B.F.Stainken et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res 2015; 21:3149-59; PMID:25850950; http://dx.doi.org/10.1158/1078-0432.CCR-14-1421
31. C.U.Louis, B.Savoldo, G.Dotti, M.Pule, E.Yvon, G.D.Myers, P.D.Khare, M.Thorn, Q.Ma, B.F.Stainken et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118:6050-6; PMID:21984804; http://dx.doi.org/10.1182/blood-2011-05-354449
32. R.A.Morgan, J.C.Yang, M.Kitano, M.E.Dudley, C.M.Laurencot, S.A.Rosenberg. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2009; 18:843-51; PMID:20179677; http://dx.doi.org/10.1038/mt.2010.24
33. E.Wang, L.C.Wang, C.Y.Tsai, V.Bhoj, Z.Gershenson, E.Moon, K.Newick, J.Sun, A.Lo, T.Baradet. et al. Generation of Potent T-cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors. Cancer Immunol Res 2015; 3:815-26; PMID:25941351; http://dx.doi.org/10.1158/2326-6066.CIR-15-0054
34. I.Caruana, B.Savoldo, V.Hoyos, G.Weber, H.Liu, E.S.Kim, M.M.Ittmann, D.Marchetti, G.Dotti. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 2015; 21:524-9; PMID:25849134; http://dx.doi.org/10.1038/nm.3833
35. V.Hillerdal, M.Ramachandran, J.Leja, M.Essand. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. BMC Cancer 2014; 14:30; PMID:24438073; http://dx.doi.org/10.1186/1471-2407-14-30
36. D.Chinnasamy, Z.Yu, S.P.Kerkar, L.Zhang, R.A.Morgan, N.P.Restifo, S.A.Rosenberg. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012; 18:1672-83; PMID:22291136; http://dx.doi.org/10.1158/1078-0432.CCR-11-3050
37. D.M.Kofler, M.Chmielewski, G.Rappl, A.Hombach, T.Riet, A.Schmidt, A.A.Hombach, C.M.Wendtner, H.Abken. CD28 costimulation impairs the efficacy of a redirected T-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing lck activatio. Mol Ther 2011; 19:760-7; PMID:21326215; http://dx.doi.org/10.1038/mt.2011.9
38. D.Chinnasamy, Z.Yu, M.R.Theoret, Y.Zhao, R.K.Shrimali, R.A.Morgan, S.A.Feldman, N.P.Restifo, S.A.Rosenberg. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 2010; 120:3953-68; PMID:20978347; http://dx.doi.org/10.1172/JCI43490
39. A.Saha, S.K.Chatterjee, K.A.Foon, F.J.Primus, S.Sreedharan, K.Mohanty, M.Bhattacharya-Chatterjee. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res 2004; 64:4995-5003; PMID:15256474; http://dx.doi.org/10.1158/0008-5472.CAN-04-0626
40. D.M.Barrett, S.A.Grupp, C.H.June. Chimeric antigen receptor- and TCR-modified T Cells enter main street and wall street. J Immunol 2015; 195:755-61; PMID:26188068; http://dx.doi.org/10.4049/jimmunol.1500751
41. M.C.Milone, J.D.Fish, C.Carpenito, R.G.Carroll, G.K.Binder, D.Teachey, M.Samanta, M.Lakhal, B.Gloss, G.Danet-Desnoyers et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17:1453-64; PMID:19384291; http://dx.doi.org/10.1038/mt.2009.83
42. L.J.Berry, M.Moeller, P.K.Darcy. Adoptive immunotherapy for cancer:the next generation of gene-engineered immune cells. Tissue Antigens 2009; 74:277-89; PMID:19775368; http://dx.doi.org/10.1111/j.1399-0039.2009.01336.x
43. M.Chmielewski, O.Hahn, G.Rappl, M.Nowak, I.H.Schmidt-Wolf, A.A.Hombach, H.Abken. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterol 2012; 143:1095-107.e2; PMID:22750462; http://dx.doi.org/10.1053/j.gastro.2012.06.037
44. M.Chmielewski, G.Rappl, A.A.Hombach, H.Abken. T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term. Gene Ther 2013; 20:177-86; PMID:22378346; http://dx.doi.org/10.1038/gt.2012.21
45. C.H.Chan, C.P.Stanners. Novel mouse model for carcinoembryonic antigen-based therapy. Mol Ther 2004; 9:775-85; PMID:15194045; http://dx.doi.org/10.1016/j.ymthe.2004.03.009
46. D.Blat, E.Zigmond, Z.Alteber, T.Waks, Z.Eshhar. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther 2014; 22:1018-28; PMID:24686242; http://dx.doi.org/10.1038/mt.2014.41
47. D.A.Zaharoff, K.W.Hance, C.J.Rogers, J.Schlom, J.W.Greiner. Intratumoral immunotherapy of established solid tumors with chitosan/IL-12. J Immunother 2010; 33:697-705; PMID:20664357; http://dx.doi.org/10.1097/CJI.0b013e3181eb826d
48. M.Kuroki, K.Hachimine, J.Huang, H.Shibaguchi, T.Kinugasa, S.Maekawa, M.Kuroki. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity. Anticancer Res 2005; 25:3725-32; PMID:16302732
49. S.Okamoto, Y.Amaishi, Y.Goto, H.Ikeda, H.Fujiwara, K.Kuzushima, M.Yasukawa, H.Shiku, J.Mineno. A promising vector for TCR gene therapy:differential effect of siRNA, 2A Peptide, and Disulfide Bond on the introduced TCR expression. Mol Ther Nucleic Acids 2012; 1:e63; PMID:23250361; http://dx.doi.org/10.1038/mtna.2012.52
50. K.Iwamura, T.Kato, Y.Miyahara, H.Naota, J.Mineno, H.Ikeda, H.Shiku. siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. Gene Ther 2012; 19:959-66; PMID:22113316; http://dx.doi.org/10.1038/gt.2011.185
51. M.Toda, L.Wang, S.Ogura, M.Torii, M.Kurachi, K.Kakimi, H.Nishikawa, K.Matsushima, H.Shiku, K.Kuribayashi et al. UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses. Int J Cancer 2011; 129:1126-36; PMID:21710495; http://dx.doi.org/10.1002/ijc.25775
52. M.Torii, L.Wang, N.Ma, K.Saito, T.Hori, M.Sato-Ueshima, Y.Koyama, H.Nishikawa, N.Katayama, A.Mizoguchi et al. Thioredoxin suppresses airway inflammation independently of systemic Th1/Th2 immune modulation. Eur J Immunol 2010; 40:787-96; PMID:20017193; http://dx.doi.org/10.1002/eji.200939724